Capecitabine and niraparib for advanced breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of two drugs, capecitabine (a chemotherapy pill) and niraparib (a targeted therapy), for people with advanced breast cancer that has stopped responding to other treatments. The goal is to see if this combination can help control the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced breast cancer that has spread or is locally advanced.
- Your tumor does not have too much HER2 protein (a marker that affects treatment).
- Your cancer is hormone-receptor negative or has stopped responding to hormone therapy.
- You have already tried taxane and anthracycline chemotherapy, unless you couldn't take them.
- You have a tumor sample available for testing, or you are willing to have a biopsy.
- You have measurable disease (tumors that can be seen on scans).
- You are generally well enough to be up and about (ECOG 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether adding a chemotherapy medicine called capecitabine (taken in smaller, regular doses) to the standard after-surgery (adjuvant) treatment can lower the chance of cancer coming back in people with early-stage, high-risk HER2-positive breast cancer. It targets patients who still had cancer left after earlier treatment or who had higher-risk tumor features.
This trial tests if adding a chemotherapy drug called capecitabine to the combination of dalpiciclib and hormone therapy works better than dalpiciclib and hormone therapy alone for advanced breast cancer that is hormone receptor-positive and HER2-negative. It is for people who have not had these treatments before.
This trial tests whether a chemotherapy pill called capecitabine can help people with low-risk triple negative breast cancer after surgery. It is for patients with stage I disease who have certain features that suggest a lower chance of recurrence.
This trial tests a combination of two targeted drugs, niraparib and abemaciclib, for people with ovarian, fallopian tube, or primary peritoneal cancer that has come back after at least two prior chemotherapies. It may be an option if you have no standard treatments left and your cancer still responds to platinum-based chemotherapy.
This trial studies whether niraparib works better when combined with bevacizumab after chemotherapy and surgery for advanced ovarian, fallopian tube, or peritoneal cancer. If you qualify, you may help researchers find a treatment plan that controls the cancer for longer.
This trial tests a drug that may help people with advanced breast cancer who have a specific genetic change (in the PALB2 gene). The drug is a PARP inhibitor, which works by targeting cancer cells that have trouble repairing their DNA.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.